MedPath

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Women's Interagency HIV Study (WIHS)

Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2019-07-18
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
4982
Registration Number
NCT00000797
Locations
🇺🇸

Georgetown Univ Med Ctr, Washington, District of Columbia, United States

🇺🇸

Chicago Consortium, Chicago, Illinois, United States

🇺🇸

University of California - San Francisco, San Francisco, California, United States

and more 2 locations

A Study To Test An Anti-Rejection Therapy After Kidney Transplantation

Phase 3
Terminated
Conditions
Kidney Transplantation
Interventions
First Posted Date
2001-08-31
Last Posted Date
2017-01-11
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
292
Registration Number
NCT00000936
Locations
🇺🇸

Ilene Blechman-Krom, Rockville, Maryland, United States

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease

Phase 3
Completed
Conditions
Lyme Disease
First Posted Date
2001-08-31
Last Posted Date
2010-08-27
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
194
Registration Number
NCT00001101
Locations
🇺🇸

Mark Klempner, Boston, Massachusetts, United States

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
36
Registration Number
NCT00000846
Locations
🇺🇸

Univ of Rochester Med Ctr, Rochester, New York, United States

🇺🇸

Univ of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Univ of Washington / Pacific Med Ctr, Seattle, Washington, United States

An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens

Phase 3
Completed
Conditions
End-Stage Renal Disease
Kidney Transplantation
Interventions
Biological: Intravenous immune globulin (IVIG)
First Posted Date
2001-08-31
Last Posted Date
2017-01-11
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
100
Registration Number
NCT00000935
Locations
🇺🇸

Ann Limberger, Rockville, Maryland, United States

A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease

Not Applicable
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2016-10-31
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Registration Number
NCT00000662
Locations
🇺🇸

Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

Not Applicable
Completed
Conditions
HIV Infections
Cytomegalovirus Retinitis
First Posted Date
2001-08-31
Last Posted Date
2021-11-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
50
Registration Number
NCT00000989
Locations
🇺🇸

UCLA CARE Center CRS, Los Angeles, California, United States

🇺🇸

Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States

🇺🇸

Memorial Sloan-Kettering Cancer Ctr., New York, New York, United States

and more 1 locations

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-10-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
60
Registration Number
NCT00000952
Locations
🇺🇸

Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States

🇺🇸

The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States

🇺🇸

HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States

and more 9 locations

A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.

Phase 1
Withdrawn
Conditions
Encephalopathy
Radiculitis
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2021-10-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Registration Number
NCT00000856

Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies

Phase 1
Completed
Conditions
HIV Infections
Pregnancy
First Posted Date
2001-08-31
Last Posted Date
2021-10-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
14
Registration Number
NCT00000888
Locations
🇺🇸

Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States

🇺🇸

Univ. of Miami Miller School of Medicine - Jackson Memorial Hosp., Miami, Florida, United States

🇺🇸

Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath